Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine

Introduction Serious infections of Pseudomonas aeruginosa (PA) in hospitals and the emergence and increase of multidrug resistance have raised an urgent need for effective vaccines. However, no vaccine has been approved to date. One possible reason for this is the limited immune response due to the lack of an efficient delivery system. Self-assembled ferritin nanoparticles are good carriers of heterogeneous antigens, which enhance the activation of immunological responses. Methods In this study, two well-studied antigen candidates, PcrV and OprI, were selected and connected to the ferritin nanoparticle by the Spytag/SpyCatcher system to generate the nanovaccine rePO-FN. Results Compared to recombinant PcrV-OprI formulated with aluminum adjuvants, intramuscular immunization with adjuvant-free rePO-FN induced quick and efficient immunity and conferred protection against PA pneumonia in mice. In addition, intranasal immunization with adjuvant-free rePO-FN enhanced protective mucosal immunity. Moreover, rePO-FN exhibited good biocompatibility and safety. Discussion Our results suggest that rePO-FN is a promising vaccine candidate, as well as, provide additional evidence for the success of ferritin-based nanovaccines.

[1]  Mingyue Tan,et al.  Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development , 2022, Frontiers in Immunology.

[2]  Yaming Shan,et al.  A biepitope, adjuvant-free, self-assembled influenza nanovaccine provides cross-protection against H3N2 and H1N1 viruses in mice , 2022, Nano Research.

[3]  Haihua Liang,et al.  Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics , 2022, Signal Transduction and Targeted Therapy.

[4]  Mohammad M. Islam,et al.  Solubility Controlling Peptide Tags of Opposite Charges Generate a Bivalent Immune Response Against Dengue ED3 Serotypes 3 and 4 , 2021, Frontiers in Immunology.

[5]  N. Tolia,et al.  Protein-based antigen presentation platforms for nanoparticle vaccines , 2021, NPJ vaccines.

[6]  S. McClean,et al.  Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors , 2021, International journal of molecular sciences.

[7]  Baoying Huang,et al.  Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice , 2021, Cellular & molecular immunology.

[8]  J. Gu,et al.  Development of a Chimeric Vaccine Against Pseudomonas aeruginosa Based on the Th17-Stimulating Epitopes of PcrV and AmpC , 2021, Frontiers in Immunology.

[9]  J. Rello,et al.  Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial , 2020, Critical Care.

[10]  Pingsai Lung,et al.  Nanoparticle formulated vaccines: opportunities and challenges. , 2020, Nanoscale.

[11]  B. Tümmler.  Emerging therapies against infections with Pseudomonas aeruginosa , 2019, F1000Research.

[12]  J. Gu,et al.  Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa , 2019, Front. Immunol..

[13]  Stephan Weise,et al.  Present and Future , 2019, A Fossil History of Southern African Land Mammals.

[14]  F. Accurso,et al.  KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  Feng Yang,et al.  Vaccination with a recombinant OprL fragment induces a Th17 response and confers serotype-independent protection against Pseudomonas aeruginosa infection in mice. , 2017, Clinical immunology.

[16]  F. Lv,et al.  Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models , 2017, Scientific Reports.

[17]  P. Kubes,et al.  Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature , 2017, The Journal of clinical investigation.

[18]  D. Farber,et al.  Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. , 2016, JCI insight.

[19]  Samuel Wagner,et al.  Bacterial type III secretion systems: specialized nanomachines for protein delivery into target cells. , 2014, Annual review of microbiology.

[20]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[21]  P. de Vos,et al.  Evaluation of oprI and oprL genes as molecular markers for the genus Pseudomonas and their use in studying the biodiversity of a small Belgian River. , 2013, Research in microbiology.

[22]  S. Lory,et al.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. , 2012, American journal of respiratory and critical care medicine.

[23]  B. Zakeri,et al.  Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin , 2012, Proceedings of the National Academy of Sciences.

[24]  P. Ricciardi-Castagnoli,et al.  Uric Acid-Driven Th17 Differentiation Requires Inflammasome-Derived IL-1 and IL-18 , 2011, The Journal of Immunology.

[25]  D. Peabody,et al.  A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2 , 2011, PloS one.

[26]  Abbas Jamali,et al.  Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: a comparative approach to conventional DNA vaccine. , 2010, Journal of virological methods.

[27]  A. Rietsch,et al.  Control of effector export by the Pseudomonas aeruginosa type III secretion proteins PcrG and PcrV , 2010, Molecular microbiology.

[28]  J. Farber,et al.  Th1-Th17 Cells Mediate Protective Adaptive Immunity against Staphylococcus aureus and Candida albicans Infection in Mice , 2009, PLoS pathogens.

[29]  A. Messadi,et al.  Association between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in an intensive care burn unit: a 5-year study, 2000-2004. , 2008, Burns : journal of the International Society for Burn Injuries.

[30]  S. Zinner.  Antibiotic use: present and future. , 2007, The new microbiologica.

[31]  K. McCullough,et al.  Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever. , 2006, Vaccine.

[32]  A. Hauser,et al.  Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. , 2001, Microbiology.

[33]  A. Alavi,et al.  Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.